Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3976500 | Brachytherapy | 2015 | 7 Pages |
Abstract
WR, WR+ Cs-131, or SBRT are all excellent treatment options for patients with early stage non-small cell lung cancer that are not candidates for lobectomy. For high risk WRs, we favor use of Cesim-131 brachytherapy. Until a prospective randomized comparative study is done to evaluate the best treatment approach for early stage NSCLC, treatment selection should be based on a multidisciplinary team approach.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Bhupesh Parashar, Jeffery Port, Shruthi Arora, Paul Christos, Samuel Trichter, Dattatreyudu Nori, A. Gabriella Wernicke,